General Information of Drug (ID: DM6VD4L)

Drug Name
KZR-616
Synonyms
Zetomipzomib; KZR-616; 1629677-75-3; UNII-O4BT6C02M2; O4BT6C02M2; (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide; D-Erythro-3-pentulose, 4,5-anhydro-1-(1-cyclopenten-1-yl)-1,2-dideoxy-4-C-methyl-2-((N-(2-(4-morpholinyl)acetyl)-L-alanyl-(betaR)-beta-hydroxy-O-methyl-L-tyrosyl)amino)-; D-erythro-3-Pentulose, 4,5-anhydro-1-(1-cyclopenten-1-yl)-1,2-dideoxy-4-C-methyl-2-[[N-[2-(4-morpholinyl)acetyl]-L-alanyl-(betaR)-beta-hydroxy-O-methyl-L-tyrosyl]amino]-; ZETOMIPZOMIB [INN]; ZETOMIPZOMIB [USAN]; KZR616; CHEMBL4297468; SCHEMBL16118957; GTPL10409; EX-A6921; BDBM50526811; AKOS040755812; compound 12 [PMID: 30380863]; HY-114419; CS-0085023; (2S,3R)-N-((S)-3-(cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide; (2S,3R)N((S)3-(Cyclopent-1-en-1-yl)-1-((R)2-methyloxiran-2-yl)-1- oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)2-(2- morpholinoacetamido)propanamido)propenamide; 4,5-ANHYDRO-1-(1-CYCLOPENTEN-1-YL)-1,2-DIDEOXY-4-C-METHYL-2-((N-(2-(4-MORPHOLINYL)ACETYL)-L-ALANYL-(.BETA.R)-.BETA.-HYDROXY-O-METHYL-L-TYROSYL)AMINO)-D-ERYTHRO-3-PENTULOSE; 4,5-Anhydro-1-(1-cyclopenten-1-yl)-1,2-dideoxy-4-C-methyl-2-((N-(2-(4-morpholinyl)acetyl)-L-alanyl-(betaR)-beta-hydroxy-O-methyl-L-tyrosyl)amino)-D-erythro-3-pentulose
Indication
Disease Entry ICD 11 Status REF
Dermatomyositis 4A41.0 Phase 2 [1]
Polymyositis 4A41.1 Phase 2 [1]
Drug Type
Small molecule
Structure
3D MOL is unavailable 2D MOL
Chemical Identifiers
Formula
C30H42N4O8
Canonical SMILES
CC(C(=O)NC(C(C1=CC=C(C=C1)OC)O)C(=O)NC(CC2=CCCC2)C(=O)C3(CO3)C)NC(=O)CN4CCOCC4
InChI
InChI=1S/C30H42N4O8/c1-19(31-24(35)17-34-12-14-41-15-13-34)28(38)33-25(26(36)21-8-10-22(40-3)11-9-21)29(39)32-23(16-20-6-4-5-7-20)27(37)30(2)18-42-30/h6,8-11,19,23,25-26,36H,4-5,7,12-18H2,1-3H3,(H,31,35)(H,32,39)(H,33,38)/t19-,23-,25-,26+,30+/m0/s1
InChIKey
GHYOCDFICYLMRF-UTIIJYGPSA-N
Cross-matching ID
PubChem CID
117607904
TTD ID
DME75T

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Immunoproteasome complex (IP) TTSJMN8 NOUNIPROTAC Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04628936) An Open-label Extension to the Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis. U.S.National Institutes of Health.
2 Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses. Front Immunol. 2023 Mar 10;14:1043680.